Berlin, Germany, May 20, 2019. In Singapore, the NCCS, a leading cancer center in Asia with award-winning medical research teams, and the SNEC, Singapore´s designated national eye center with an internationally recognized research institute, are now offering an important eye-preserving cancer treatment to the region. Both centers decided to inaugurate an ophthalmic brachytherapy service together for the treatment of uveal melanomas and retinoblastomas.
I-125 Ophthalmic Seeds - Individual Eye Tumor Treatment with COMS Eye Applicators
The two centers have already treated the first eye cancer patients with Eckert & Ziegler BEBIG´s I-125 Ophthalmic Seeds and are the only medical provider offering ophthalmic brachytherapy in Singapore to date. With this form of radiotherapy, a radioactive plaque containing iodine-125 is sutured to the wall of the eye, adjacent to the tumor, and left in place for several days until the required dose of radiation has been delivered. The availability of iodine seeds with a broad range of activity which can be customized into a plaque specific for each patient enables the treatment of the widest range of tumor sizes in children and adults.
'The management of ocular tumors is dependent on the size and location of the ocular lesion and the overall stage of the tumor. As an alternative to removing the whole eye, ophthalmic brachytherapy allows the preservation of the eyeball and vision. Therefore, it is preferred when clinically appropriate. When indicated, brachytherapy is the standard of care for intraocular tumors, enabling the patient to preserve long term vision with a significant improvement in the quality of life, making it a cost effective therapeutic modality.' explains Dr. Gavin Tan Siew Wei, Assistant Professor, Ophthalmology & Visual Sciences Academic Clinical Program.
For the NCCS, the addition of ophthalmic brachytherapy to their services together with the SNEC, which is funding the program, further strengthens their multidisciplinary approach in the fight against cancer. As leading centers in the region, the NCCS and SNEC are striving to offer a complete treatment portfolio while delivering the best individual patient care. The decision to use I-125 Ophthalmic Seeds by Eckert & Ziegler BEBIG was due to the good reputation of the seeds, their long record of users and the training and service that was offered to the centers to enable a quick and smooth start with the new treatment option.
About Eckert & Ziegler BEBIG
My partner in brachytherapy and radiation therapy
Eckert & Ziegler BEBIG is a European-based group active in the medical device segment of the health care industry. Its core business is the production and distribution of medical products for the treatment of cancer using brachytherapy. The company headquarters are in Germany, with production facilities in Germany and in the USA, as well as offices throughout Europe, Asia and the USA. In addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and agents to support the international marketing and distribution of its product line. The company's products and equipment are intended for use by oncologists, radiotherapists, urologists, ophthalmologists and medical physicists. Eckert & Ziegler BEBIG employs approximately 145 people.
Marketing Communication Manager